In patients with ulcerative colitis, initiation of biologic therapy within 12 months of diagnosis is linked to a lower risk for disease progression than later initiation.

For people with UC, ‘feeling better’ is just the start. Learn why tissue-level (histological) healing is becoming the new ...

Researchers have used advanced genetic sequencing on a Brisbane family to identify a gene mutation linked to ulcerative colitis, a type of inflammatory bowel condition, sparking hopes of new ...

Icotyde is the first targeted oral peptide IL‑23 receptor antagonist, designed to interrupt a core psoriasis inflammatory axis while avoiding injection-based administration typical of IL‑23 biologics.

News and commentary from the world of gastroenterology and hepatology ...

A global meta-analysis finds that anemia affects 37% of patients with inflammatory bowel disease, highlighting gaps in ...

On March 18, 2026, Sandoz announced a new license, development, and commercialization partnership agreement with Samsung ...

Alex Lyons has Ulcerative Colitis one of the most common forms of inflammatory bowel disease.

By Sriparna Roy March 18 (Reuters) - The U.S. Food and Drug Administration has approved Johnson & Johnson's oral pill for ...

ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety profile in a once-daily pill Approval supported by four phase 3 studies that met ...

Johnson & Johnson’s Icotyde receives US FDA approval for first-line systemic treatment of plaque psoriasis with a targeted oral peptide: Spring House, Pennsylvania Friday, March ...